Co-Chairs:
John Marshall, MD Lombardi Cancer Center Georgetown University Washington, DC, USA		Alberto Sobrero, MD Hospital San Martino Genoa, Italy
Faculty:
Dirk Arnold, MD Martin Luther University Halle, Germany David Cunningham, MD Royal Marsden Hospital Surrey, United Kingdom Edward Chu, MD Yale Cancer Center Yale University New Haven, Connecticut, USA		David Ilson, MD, PhD Memorial Sloan-Kettering Cancer Center New York, New York, USA Axel Grothey, MD Mayo Clinic Rochester, Minnesota, USA Christopher Twelves, MD Leeds Cancer Center St James’s University Hospital Leeds, United Kingdom

		Welcome and Introduction Co-chairs: John Marshall, MD                 Alberto Sobrero, MD
6:30 PM		Debate I What Constitutes Optimal Initial CHEMOTHERAPY for Metastatic Colorectal Cancer in a Patient with Good Performance Status?
		FOLFOX or FOLFIRI: David Ilson, MD, PhD XELOX or XELIRI: Alberto Sobrero, MD
6:55 PM		Panel Commentary
7:00 PM		Debate II Should Chemotherapy plus a Targeted Agent Be the New Standard for Initial Management of Metastatic Colorectal Cancer?
		PRO: Edward Chu, MD CONTRA: Dirk Arnold, MD
7:25 PM		Panel Commentary
7:30 PM		Debate III What Is the Best Multidisciplinary Approach to Resectable Gastric Cancer?
		Perioperative Chemotherapy: David Cunningham, MD Postoperative Chemoradiotherapy: John Marshall, MD
7:55 PM		Panel Commentary
8:00 PM		Debate IV Capecitabine-Based Adjuvant Chemotherapy (+/- Bevacizumab) is Preferred to 5FU-Based Chemotherapy (+/- Bevacizumab) for Stage II/III Colorectal Cancer.
		PRO: Christopher Twelves, MD CONTRA: Axel Grothey, MD
8:25 PM		Panel Commentary
8:30 PM		Concluding Remarks Co-chairs: John Marshall, MD                 Alberto Sobrero, MD

Dilemmas in Colorectal and Gastric Cancer Management: Global Perspectives is intended for medical oncologists, radiation oncologists, surgeons, and other healthcare providers interested in the management of colorectal and gastric cancer.

The treatment of gastric and colorectal cancers remains a challenge and uncertainty remains for oncologists despite improvement in the past decade. In the era of molecular biology, it is important to tailor therapy for each individual patient. Determining which treatment approach is most appropriate for a given patient requires careful attention to patient-specific and tumor-specific considerations. New screening tools may enable oncologists to tailor specific treatments to individual patients to maximize efficacy.  Novel combination drug regimens and treatment strategies are continually being evaluated in clinical trials resulting in improved outcomes for patients with gastric and colorectal cancers. The decision-making process for oncology healthcare professionals involved in the treatment of gastric and colorectal cancers is challenging, thereby requiring in-depth knowledge of current clinical and experimental data for the appropriate integration of new therapeutics into clinical practice.  

After successfully completing this educational activity, participants should be able to:

• Outline data from recent clinical trials involving combination chemotherapy regimens for initial treatment of patients with metastatic colorectal cancer
• Describe recent clinical trial data integrating antiangiogenic agents and EGFR inhibitors into chemotherapy regimens for the initial management of metastatic colorectal cancer
• Explain the association between the KRAS mutational status and efficacy of available anti-EGFR agents so that the appropriate choice of targeted agents may be selected for specific patients
• Identify the optimal multidisciplinary approach to resectable gastric cancer based on recent clinical trial evidence
• Review current and emerging regimens for adjuvant treatment of patients with Stage II/III colorectal cancer including considerations that might be taken into account when selecting therapeutic regimens

Postgraduate Institute for Medicine requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose any real or apparent conflict of interest they may have as related to the content of this activity. All identified conflicts of interest are thoroughly vetted by PIM for fair balance, scientific objectivity of studies mentioned in the materials or used as the basis for content, and appropriateness of patient care recommendations.

This educational activity may contain discussion of published or and/or investigational uses of agents that are not indicated by the US Food and Drug Administration. Postgraduate Institute for Medicine, PRIME Oncology, or Roche Laboratories Inc do not recommend the use of any agent outside of the labeled indications.

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of PIM, PRIME Oncology, or Roche Laboratories Inc. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Event staff will be glad to assist you with any special needs (physical, dietary, etc.). Please contact Michael Checkoway prior to the live event at michael.checkoway@primeoncology.org or 678-892-1358.